The Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency, has handed down a negative opinion on the approval of combination ipilimumab and nivolumab for the frontline treatment of advanced renal cell carcinoma. The main reason for this decision is the lack of a nivolumab monotherapy arm in the study. This decision currently leaves a treatment with up to 16 percent complete response rate in intermediate and poor risk disease groups unavailable to European
World Kidney Cancer Q&A Day is on 21 June 2018
Leading up to the second World Kidney Cancer Day, people all around the world will be asking questions and looking for answers to help raise global awareness of kidney cancer.
World Kidney Cancer Day provides the opportunity for patients, carers, their friends and supporters, health care professionals and local kidney cancer organisations, to come together to raise awareness and start to answer those questions that will make a difference to stemming
Note: The following summary was prepared for the benefit of patient organisations who focus on kidney cancer. While this summary has been medically reviewed, the information contained herein is based upon public data shared at this meeting and is not intended to be exhaustive. Patients should ask their physician about any information that pertains to their care.
The American Society of Clinical Oncology (ASCO) Conference in Chicago June 1-5 2018 brought together oncology professionals, patient
Our 8th IKCC Conference for kidney cancer patient organisations recently held in Mexico City, Mexico was a huge success with over 50 kidney cancer patient advocates from 25 countries attending . Throughout the three-day meeting patient organisation leaders learned about latest developments in kidney cancer care, discussed active patient involvement and shared experiences with national healthcare policies. This meeting was held alongside a Clinical Experts meeting hosted by the <a href="http://www.larcg.org/
We are pleased to present the Book of Courage and Hope. This collection of the stories of patient experiences and the support provided by our affiliates in many of the countries represented among our Affiliates helps to demonstrate the important work of our Affiliates, and of the International Kidney Cancer Coalition in supporting and encouraging those Affiliates. Read about the important work of kidney cancer care around the world.
Our International Kidney Cancer Patient Charter was created to ensure that the more than one million people living with kidney cancer worldwide have access to the best available treatment, care, information and support. The Charter is based on a survey extended to 34 patient group leaders with a special interest in kidney cancer, located in 20 countries spread over 6 continents.